GILD.BA Gilead Sciences, Inc.
Company Analysis
Latest News
Gilead Bets Big on Solid-Tumor Immunotherapy With Vir Deal — But Can a $1.87 Billion Gamble Justify an 8.7% Rally?
Shares of Gilead Sciences surged 8.7% to ARS 64,650 on October 15, the sharpest single-day jump in months, after the company announced a sweeping oncology...
🟢 Gilead Sciences is trading 8.66% up today after Vir solid-tumor T-cell engager deal
Gilead Sciences is trading at ARS 64,650, up +8.66%, with the move most plausibly tied to its Vir Biotechnology oncology deal. - Announced October 14, it...
🟢 Gilead Sciences is trading 4.16% up today after likely Vir solid-tumor collaboration
Gilead Sciences is trading at ARS 61,975, up 4.16%, with its newly disclosed collaboration with Vir Biotechnology the most likely catalyst cited in coverage. -...
Gilead Expands AI and Oncology Partnerships to Advance Research
Gilead Sciences extended its artificial intelligence and DevOps partnership with Cognizant for another five years. The agreement aims to expand AI use across...
Gilead Secures EU Approval for Trodelvy Combo in First-Line Breast Cancer
Gilead Sciences received European Commission approval for Trodelvy in combination with Merck’s Keytruda. The therapy is indicated for the first-line treatment...
🟢 Gilead Sciences is trading 4.23% up today after product sales rose 8% in Q2
Gilead Sciences is trading 4.23% up at ARS 56675.00 after continued investor response to its August 4 second-quarter report, which showed product sales rising...
Gilead Sciences upgraded to buy, court blocks HIV drug imports
Wall Street Zen upgraded Gilead Sciences from hold to buy on Saturday. This rating change follows a U.S. appeals court ruling that upheld an injunction against...
🟢 Gilead Sciences is trading 4% up today after EU backing for Trodelvy combo
Gilead Sciences is trading 4% up at ARS 53,725 following a positive regulatory recommendation from the European Medicines Agency (EMA). • The EMA’s CHMP...
Gilead Wins EU Backing for Trodelvy Combo, Reducing Cancer Risk 35%
Gilead Sciences received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for its drug...
Gilead Sciences downgraded by Leerink, citing HIV and cancer market concerns
Leerink Partners downgraded Gilead Sciences on July 21, 2026. The firm adjusted its rating from Outperform to Market Perform. Analysts also lowered the price...
Gilead Sciences tests Ebola antiviral in Congo, targeting high-fatality strain
Gilead Sciences launched a clinical trial in the Democratic Republic of Congo for an experimental antiviral. The treatment targets the Bundibugyo strain of...
🔴 Gilead Sciences is trading 5.1% down today amid biotech sector sell-off and geopolitical tensions
Gilead Sciences is trading 5.1% down at ARS 50,750.00 as part of a broader pullback in biotechnology and risk assets. • Biotechnology stocks are down more...
🔴 Gilead Sciences, Inc. is trading 4.16% down
GILD.BA is trading at $51225.00, down 4.16%.
🟢 GILD.BA gains 0.4% as positive HIV trial results and European Trodelvy approval buoy sentiment
GILD.BA is trading 0.4% up today at $53,775, driven by significant company-specific news: * Gilead announced successful Phase 3 trial results for its...
🔴 GILD.BA is trading 4.5% down today despite HSBC upgrade to Buy
GILD.BA is trading 4.5% down today at $50,850, as broader market weakness and profit-taking outweigh a significant analyst upgrade. • HSBC upgraded Gilead...
Gilead Sciences Upgraded to Buy, HSBC Cites HIV and Oncology Strength
HSBC upgraded Gilead Sciences (GILD.BA) from Hold to Buy. The bank raised its price target for the stock from $133.00 to $155.00. Analysts suggest the market...
🟢 GILD.BA is trading 4.6% up today, extending a multi-day rebound amid broader biotech sector interest
GILD.BA is trading 4.6% up today at $51,725.00 as the stock extends a strong multi-day rebound from late June levels despite a lack of fresh company-specific...
🔴 GILD.BA is trading 0.1% down today as it consolidates Friday's FDA-driven gains
GILD.BA is trading 0.1% down today at $49,020, giving back a small portion of Friday’s FDA-approval rally. • The stock surged 3.1% on June 26 after the U.S....
🟢 GILD.BA is trading 3.1% up today after FDA approval of Trodelvy for first-line breast cancer treatment
GILD.BA is trading 3.1% up now at $49,320 after the U.S. FDA approved Gilead’s antibody-drug conjugate Trodelvy for first-line treatment of metastatic...
Gilead Wins FDA Approval for Trodelvy, Expanding into First-Line Breast Cancer
The U.S. Food and Drug Administration approved Gilead Sciences’ antibody-drug conjugate, Trodelvy, for first-line triple-negative breast cancer. The approval...